fda approval for tirzepatide New weight-loss treatment becomes first FDA-approved drug sleep apnea Weight Loss Drug Tirzepatide Now

This synthetic hexapeptide belongs to the growth factor family and demonstrates properties in stimulating growth hormone release [5]

Patients not on treatment or on other antihyperglycemic agents entered a run-in treatment period of up to 12 weeks duration with metformin monotherapy (dose of greater than or equal to 1500 mg per day) which included washout of medications other than metformin, if applicable

CNS Drugs 26 , 297307 (2012)

Broadly, your options are 1) continue on the same dose of GLP-1 2) gradually lower your dose of GLP-1 to find the minimum effective dose that works for you 3) taper off your dose of GLP-1